CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 3, 2009, Pages 708-714

  De Andrade, Camilla F C G ^a   Bigni, Ricardo ^a   Pombo De Oliveira, Maria S ^a   Alves, Gilda ^a   Pereira, Denise A ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

CD26; Dipeptidyl peptidase; DPPIV; Immunophenotype; Inhibition; Leukemia; Sitagliptin

Indexed keywords

CD19 ANTIBODY; CD19 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CD61 ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DIPEPTIDYL PEPTIDASE IV; DNA NUCLEOTIDYLEXOTRANSFERASE; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; SITAGLIPTIN; T6 ANTIGEN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CELL MEMBRANE; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; T CELL LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; BLOOD; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KINETICS; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; REFERENCE VALUE; YOUNG ADULT;

ADOLESCENT; CELL MEMBRANE; CHILD; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; KINETICS; LYMPHOCYTE ACTIVATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRAZINES; REFERENCE VALUES; TRIAZOLES; YOUNG ADULT;

EID: 70749139928     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802334800     Document Type: Article

References (35)

1. De Meester I, Korom S, Van Damme J, Scharpe A S. CD26, let it cut or cut it down. Immunol Today 1999;20:367-375.
2. Kaèhne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: A cell surface peptidase involvedin regulatingTcell growth. Int J Mol Med 1999;4:3-15.
3. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.
4. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, Boykins R, Unsworth E, Norcross MA. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)- mediated cleavage. J Exp Med 1997;186:1865-1872.
5. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, Opdenakker G, De Clercq E, Scharpe S, Van Damme J. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998;273:7222-7227.
6. Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, Hu H, Kato A, Sakai Y, Liu H, Honjo T, Nomoto A, Iwamoto A, Morimoto C, Nagai Y. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 1998;95:6331-6336.
7. Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, Mantovani A, Augustyns K, Bal G, Haemers A, Lambeir AM, Scharpe A S, Van Damme J, De Meester I. Truncation of macrophage-derived chemokine by CD26/dipeptidylpeptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988-3993.
8. Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts JP,DetheuxM,ParmentierM,DeMeester I,ScharpeA S, Van Damme J. CD26/dipeptidyl-peptidase IV downregulates the eosinophil chemotactic potency, but not the anti-HIVactivity of human eotaxin by affecting its interactionwithCCchemokine receptor. J Immunol 1999;162:4903-4909.
9. Mentlein R, Dahms P, Grandt D, Kruè ger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993;49:133-144.
10. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 1989;83:1533-1540.
11. Bongers J, Lambros T, Ahmad M, Heimer EP. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormonereleasing factor and analogs. Biochim Biophys Acta 1992;1122:147-153.
12. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagons like peptide-1 (7 -36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-835.
13. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585-3596.
14. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL. Regulation of thebiological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 1997;15:673-677.
15. Wrenger S, Kaèhne T, Bohuon C,WegloÈ hner W, Ansorge S, Reinhold D. Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV). FEBS Lett 2000;466:155-159.
16. Hinke SA, Pospisilik JA, Demuth HU, Mannhart S, Kuhn- Wache K, Hoffmann T, Nishimura E, Pederson RA, McIntosh CH. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products andDPIV-resistant analogs. J Biol Chem2000;275:3827-3834.
17. Shipp MA, Look AL. Hematopoietic differentiation antigens that are membrane associated enzymes: Cutting is the key! Blood 1993;82:1052-1070.
18. Buhling F, Junker U, Reinhold D, Neubert K, Jager L, Ansorge S. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995;45:47-51.
19. Buhling F, Dunz D, Reinhold D, Ulmer AJ, Ernst M, Flad HD, Ansorg S. Expression and functional role of dipeptidyl peptidase IV on human natural killer cells. Nat Immun 1994;13:270-279.
20. Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schlossman SF, Morimoto C. Enhancement of antigeninduced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 1994;91:3082-3086.
21. Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C. Characterization of adenosine deaminase binding to human CD26 on T-cells and its biologic role in immune response. J Immunol 1996;156:1349-1355.
22. Dong RP, Tachibana K, Hegen M, Munakata Y, Cho D, Schlossman SF, Morimoto C. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997;159(12): 6070-6076.
23. Kobayashi S, Ohnuma K, Uchiyama M, Iino K, Iwata S, Dang NH, Morimoto C. Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation. Blood 2004;103(3):1002-1010.
24. Ishii T, Ohnuma K, Murakami A, Takasawa N, Kobayashi S, Dang NH, Schlossman SF, Morimoto C. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA 2001;98(21):12138-12143.
25. Dang NH, Morimoto C. CD26: An expanding role in immune regulation and cancer. Histol Histopathol 2002;17:1213-1226.
26. Sedo A, Maĺk R. Dipeptidyl peptidase IV-like molecules: Homologous proteins or homologous activities? Biochim Biophys Acta 2001;550:107-116.
27. Busek P, Malik R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004;36(3):408-421.
28. Thornberry NA, Weber AE. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007;7(6):557-568.
29. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[ 1,2,4]triazolo[4,3-a] pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-151.
30. Bani B. Leukemia diagnosis. London: Blackwell Science; 1997.
31. Béné MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-1786.
32. Amlot PL, Tahami F, Chinn D, Rawlings E. Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Clin Exp Immunol 1996;105(1):176-182.
33. Klobusická M, Babusiková O. Immunophenotypic characteristics of T-acute lymphoblastic leukemia cells in relation to DPPIV enzyme expression. Neoplasma 1998;45(4):237-242.
34. Klobusická M, Babusiková O. Expression of CD26 and DPPIV in T-acute lymphoblastic leukemia: Comparison of immunocytochemistry with enzyme cytochemistry. Neoplasma 1999;46(5):299-303.
35. Ruiz P, Zacharievich N, Shenkin M. Multicolor cytoenzymatic evaluation of dipeptidyl peptidase IV (CD26) function in normal and neoplastic human T-lymphocyte populations. Clin Diagn Lab Immunol 1998;5(3):362-368.